BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 19336523)

  • 1. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
    Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
    Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma.
    Hsieh JL; Lee CH; Teo ML; Lin YJ; Huang YS; Wu CL; Shiau AL
    Cancer Sci; 2009 Mar; 100(3):537-45. PubMed ID: 19134007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter.
    Sagawa T; Takahashi M; Sato T; Sato Y; Lu Y; Sumiyoshi T; Yamada Y; Iyama S; Fukaura J; Sasaki K; Hamada H; Miyanishi K; Takayama T; Kato J; Niitsu Y
    Mol Ther; 2004 Dec; 10(6):1043-50. PubMed ID: 15564136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase-dependent oncolytic adenovirus for cancer treatment.
    Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
    Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
    Kuroda T; Rabkin SD; Martuza RL
    Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
    Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy.
    Leja J; Dzojic H; Gustafson E; Oberg K; Giandomenico V; Essand M
    Clin Cancer Res; 2007 Apr; 13(8):2455-62. PubMed ID: 17438105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
    Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
    Ren XW; Liang M; Meng X; Ye X; Ma H; Zhao Y; Guo J; Cai N; Chen HZ; Ye SL; Hu F
    Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.